Minerva Neurosciences, Inc. (NERV)
| Market Cap | 50.70M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -27.71M |
| Shares Out | 6.99M |
| EPS (ttm) | -4.72 |
| PE Ratio | n/a |
| Forward PE | 11.21 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 83,580 |
| Open | 7.99 |
| Previous Close | 7.85 |
| Day's Range | 6.65 - 8.50 |
| 52-Week Range | 1.26 - 13.22 |
| Beta | 0.23 |
| Analysts | Hold |
| Price Target | 11.00 (+51.72%) |
| Earnings Date | Nov 7, 2023 |
About NERV
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. Minerva Neurosciences, Inc.... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to one analyst, the rating for NERV stock is "Hold" and the 12-month stock price forecast is $11.0.
News
Minerva Neurosciences Reports 2023 Third Quarter Financial Results and Business Updates
BURLINGTON, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central ner...
Minerva Neurosciences Reports 2023 Second Quarter Financial Results and Business Updates
BURLINGTON, Mass., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central ner...
Minerva Neurosciences Announces $20 Million in Private Placement Priced at a Premium to Market
BURLINGTON, Mass., June 28, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central ner...
Minerva Neurosciences Reports 2023 First Quarter Financial Results and Business Updates
BURLINGTON, Mass., May 15, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nerv...
Minerva Neurosciences Announces Update on its New Drug Application (NDA) for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia
FDA confirms acceptance of the filing of the NDA for roluperidone Application has been granted a standard review FDA has assigned a Prescription Drug User Fee Act (PDUFA) goal date of February 26, 202...
Minerva Neurosciences to Report First Quarter 2023 Financial Results and Business Updates on May 15, 2023
BURLINGTON, Mass., May 08, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nerv...
Minerva Neurosciences Reports Fiscal Year 2022 Fourth Quarter And Year End Financial Results And Business Updates
Company to Host Conference Call Today at 8:30 a.m. ET Company to Host Conference Call Today at 8:30 a.m. ET
Minerva Neurosciences to Report Fiscal Year 2022 Financial Results and Business Updates on March 8, 2023
Management to Host Conference Call Management to Host Conference Call
Minerva Neurosciences Reports Third Quarter 2022 Financial Results and Business Updates
Company To Host Live Webcast Today at 8:30 a.m. ET Company To Host Live Webcast Today at 8:30 a.m. ET
Minerva Neurosciences to Report Third Quarter 2022 Financial Results and Business Updates on November 9, 2022
BURLINGTON, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central ner...
Minerva Neurosciences to request meeting with FDA about schizophrenia drug
Minerva Neurosciences Inc. NERV, +7.61% said Monday that it received a refusal to file letter from the Food and Drug Administration for its application for roluperidone as a treatment for patients wit...
Minerva Neurosciences Receives Refusal to File Letter from FDA for its New Drug Application for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia
BURLINGTON, Mass., Oct. 17, 2022 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central ner...
Minerva Neurosciences Announces Listing Transfer to Nasdaq Capital Market
BURLINGTON, Mass., Sept. 09, 2022 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central ne...
Minerva Neurosciences Submits New Drug Application to FDA for Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia
WALTHAM, Mass., Aug. 22, 2022 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervou...
Minerva Neurosciences Reports Second Quarter 2022 Financial Results and Business Updates
Company Continues to Prepare for Potential Submission of an NDA for Roluperidone in the Third Quarter of 2022 Company Continues to Prepare for Potential Submission of an NDA for Roluperidone in the Th...
Minerva Neurosciences Reports First Quarter 2022 Financial Results and Business Updates
Company Expects to Submit an NDA for Roluperidone, Subject to FDA Guidance, in the Third Quarter of 2022 Company Expects to Submit an NDA for Roluperidone, Subject to FDA Guidance, in the Third Quarte...
Minerva Outlines Next Steps For US Application For Schizophrenia Candidate
Minerva Neurosciences Inc (NASDAQ: NERV) received the official meeting minutes from the Type C meeting with the FDA regarding the development of roluperidone for negative symptoms in schizophrenia. Th...
Minerva Neurosciences Provides Update from Type C Meeting with FDA and Next Steps in Preparation for Submission of a New Drug Application (NDA) for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia
Company to Host Webcast Wednesday, April 13, 2022 at 11am ET Company to Host Webcast Wednesday, April 13, 2022 at 11am ET
Minerva Neurosciences Reports Fourth Quarter 2021 Financial Results and Business Updates
WALTHAM, Mass., March 01, 2022 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV) a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat cen...
Minerva Neurosciences Announces Publication of Roluperidone Phase 3 Study Results in Schizophrenia Bulletin
Trial Results Confirm the Potential of Roluperidone To Treat Negative Symptoms and Improve Everyday Functioning in Patients with Schizophrenia Trial Results Confirm the Potential of Roluperidone To Tr...
Minerva Neurosciences Reports Third Quarter 2021 Financial Results and Business Updates
Company to Host Conference Call Today at 8:30 a.m. ET
Minerva Neurosciences Announces FDA Recommendation for Type C Meeting to Discuss Evidence for Use of Roluperidone as Monotherapy for the Treatment of Negative Symptoms in Patients with Schizophrenia in Advance of Potential NDA Submission
WALTHAM, Mass., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervou...
Minerva Neurosciences to Report Third Quarter 2021 Financial Results and Business Updates on November 8
Management to Host Conference Call Management to Host Conference Call
Minerva Neurosciences Announces Promotion of Geoff Race to President
Frederick Ahlholm is Named Chief Financial Officer as Company Prepares to Submit a Pre-NDA Meeting Request to FDA
Minerva Posts Positive Bioequivalence Results For Schizophrenia Candidate Formulations
Minerva Neurosciences Inc (NASDAQ: NERV) announced results from a bioequivalence study comparing roluperidone formulations used in Phase 2b and Phase 3 trials and the planned commercial formulation. ...